Autem Therapeutics
PrivateLast Round
Series A
Extension
Jun 6, 2022
Total Funding Raised
$14M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Autem Therapeutics operates in Healthcare & Life Sciences and is based in Hanover, New Hampshire. Its latest recorded funding round was a Series A Extension round in June 2022.
Autem Therapeutics is an oncology and bioelectric technology company developing a non-invasive, non-toxic treatment platform for solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Hardware + Subscription, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Autem Therapeutics Comparables
Compare Autem Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TheraBionic | 86% | |
| EMulate Therapeutics | 85% | |
| LifeBridge Innovations, PBC | 84% |
For institutional investors. Book with your work email.
Autem Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jun 6, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Autem Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Zentynel Frontier Investments | Series A Extension |
| Spectra Investimentos | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 12, 2026
Monthly visitors grew 65% MoM.
- Jul 26, 2026
Monthly visitors increased 73% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 9, 2026
On Nov 9th '26, Autemtherapeutics receives a $100K venture philanthropy grant from The Musella Foundation to support AutEMsys research and early clinical studies in glioblastoma.
For institutional investors. Book with your work email.
Autem Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Autem Therapeutics's valuation, stock price, and market status.
Is Autem Therapeutics a public or private company?
Autem Therapeutics is a private company.
What is the current stock price of Autem Therapeutics?
Autem Therapeutics is a private company, so its shares have no public market price. Caplight tracks Autem Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Autem Therapeutics worth (valuation)?
Valuation information for Autem Therapeutics is not publicly available.
Can I buy Autem Therapeutics stock?
Autem Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Autem Therapeutics's last funding round?
Autem Therapeutics's most recent funding round was Series A Extension on June 6, 2022.
Who are the main investors in Autem Therapeutics?
Key investors in Autem Therapeutics include Zentynel Frontier Investments.
Will Autem Therapeutics IPO soon?
No public IPO plans have been announced for Autem Therapeutics.
How can I track Autem Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Autem Therapeutics's shares on secondary markets.